Available Tests

Hereditary Cancer Program Panel

The Centre for Clinical Genomics (CCG) is pleased to announce its 14 gene Hereditary Cancer Program Panel is now available to patients across Canada. This panel replaced BRCA1/2 testing in British Columbia in October 2014.

Summary of genes on the HCPP

Gene Syndrome
BRCA1 Hereditary Breast/Ovarian Cancer
TP53 Li Fraumeni
PTEN PTEN Harmartoma Tumour Syndrome
CDH1 Hereditary Diffuse Gastric Cancer
STK11 Peutz-Jeghers
MLH1 Lynch Syndrome
MUTYH MYH-Associated Polyposis
APC Familial Adenomatous Polyposis
SMAD4 Juvenile Polyposis

Copy number changes

MLPA for copy number changes is offered for BRCA1, BRCA2, MLH1 and MSH2 upon request.


  • More comprehensive test: includes the 14 genes most commonly tested when screening for hereditary breast, ovarian, and colorectal cancer syndromes.
  • Only clinically relevant genes: only genes with clinical utility are included on the panel.
  • Saves money: eliminates ordering single gene tests one after another.
  • Saves time: shortens the time from initial consultation to diagnosis by testing all genes at once.
  • Up to date: panel is reviewed and revised to reflect genes desired by experts.
  • Feedback encouraged: panel users are welcome to suggest additional gene targets for future panel releases.

Ordering the panel

In British Columbia: Referrals for this assay must be requested through the BC Cancer Agency Hereditary Cancer Program.

Outside British Columbia: please contact us for details and requisition forms.

Turnaround time of panel

The current turnaround time is 8-10 weeks. A list of ACMG 1, 2, and 3 variants with clinical interpretation will be reported by the Cancer Genetics Laboratory.


We are offering the 14 gene panel at the same cost as simply testing BRCA1/2. Please contact us for further details.


Variants in exons 5, 11, 12, 13, 14, and 15 of PMS2 are not reported.


The development of the BRCA1/2 assay is described in Bosdet et al. 2013.